PMID- 26406406
OWN - NLM
STAT- MEDLINE
DCOM- 20161018
LR  - 20220318
IS  - 1875-8592 (Electronic)
IS  - 1574-0153 (Linking)
VI  - 15
IP  - 6
DP  - 2015
TI  - MiR-4728-3p could act as a marker of HER2 status.
PG  - 807-14
LID - 10.3233/CBM-150524 [doi]
AB  - BACKGROUND: MiR-4728 was recently identified to be related with HER2 in several 
      cell lines and limited tissue samples. OBJECTIVE: To investigate whether miR-4728 
      could predict HER2 status in a larger cohort. METHODS: The expression of 
      miR-4728-3p and miR-4728-5p was identified in breast cancer (BC) and gastric 
      cancer (GC) tissues with different HER2 status using quantitative reverse 
      transcription polymerase chain reaction (qRT-PCR) and fluorescence in situ 
      hybridization (FISH). An additional 22 plasma samples was investigated to explore 
      the potential application of miR-4728 as a non-invasive biomarker in predicting 
      HER2 status. RESULTS: MiR-4728-3p and miR-4728-5p were significantly up-regulated 
      in HER2-positive patients compared with HER2-negative patients. Compared with the 
      expression in adjacent normal tissues, miR-4728-3p and miR-4728-5p were both 
      elevated in HER2-negative and HER2-positive GC tissues but only miR-4728-3p in 
      HER2-positive BC tissues. Further analyses revealed that miR-4728-3p had greater 
      ability than miR-4728-5p in discriminating subgroups with different intensity of 
      HER2 staining in both BC and GC patients. In addition, miR-4728-3p but not 
      miR-4728-5p was significantly up-regulated in plasma of BC patients with positive 
      HER2. CONCLUSIONS: MiR-4728-3p had better ability in distinguishing patients with 
      different status of HER2 than miR-4728-5p. And plasma miR-4728-3p might act as a 
      non-invasive biomarker in predicting HER2 status.
FAU - Li, Hai
AU  - Li H
AD  - Department of Pathology, First Affiliated Hospital of Nanjing Medical University, 
      Nanjing, Jiangsu, China.
FAU - Zhou, Xin
AU  - Zhou X
AD  - Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 
      Nanjing, Jiangsu, China.
FAU - Zhu, Jun
AU  - Zhu J
AD  - Department of Radiation Oncology, Jiangsu Cancer Hospital, Nanjing, Jiangsu, 
      China.
FAU - Cheng, Wenfang
AU  - Cheng W
AD  - Department of Gastroenterology, First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Zhu, Wei
AU  - Zhu W
AD  - Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 
      Nanjing, Jiangsu, China.
FAU - Shu, Yongqian
AU  - Shu Y
AD  - Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 
      Nanjing, Jiangsu, China.
FAU - Liu, Ping
AU  - Liu P
AD  - Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 
      Nanjing, Jiangsu, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Cancer Biomark
JT  - Cancer biomarkers : section A of Disease markers
JID - 101256509
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MIRN4728 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biomarkers, Tumor/*genetics
MH  - Breast Neoplasms/*genetics/metabolism/pathology
MH  - Carcinoma, Ductal, Breast/*genetics/metabolism/pathology
MH  - Carcinoma, Lobular/*genetics/metabolism/pathology
MH  - Case-Control Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - MicroRNAs/*genetics
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Prognosis
MH  - RNA, Messenger/genetics
MH  - Real-Time Polymerase Chain Reaction
MH  - Receptor, ErbB-2/*genetics/metabolism
MH  - Receptors, Estrogen/metabolism
MH  - Receptors, Progesterone/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Stomach Neoplasms/*genetics/metabolism/pathology
OTO - NOTNLM
OT  - HER2
OT  - marker
OT  - miR-4728
EDAT- 2015/09/26 06:00
MHDA- 2016/10/19 06:00
CRDT- 2015/09/26 06:00
PHST- 2015/09/26 06:00 [entrez]
PHST- 2015/09/26 06:00 [pubmed]
PHST- 2016/10/19 06:00 [medline]
AID - CBM--1-CBM524 [pii]
AID - 10.3233/CBM-150524 [doi]
PST - ppublish
SO  - Cancer Biomark. 2015;15(6):807-14. doi: 10.3233/CBM-150524.